Ergoteles’s MacroGenics MGNX Stock Holding History

Ergoteles’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-75,200	Closed	-$222K	–	1806
2022 Q2	$222K	Buy	+75,200	New	+$395K	0.01%	1267
2022 Q1	–	Sell	-32,115	Closed	-$515K	–	1473
2021 Q4	$515K	Buy	+32,115	New	+$604K	0.02%	630

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's MGNX Position: Q3 2022 in Review

Ergoteles sold out of MacroGenics (MGNX) in Q3 2022, closing a stake of 75,200 shares — an estimated $222K sold.

Ergoteles first reported a position in MGNX in Q4 2021 and held it in 2 quarters. The position peaked at $515K in Q4 2021. 135 funds tracked by Wall St. Rank hold MGNX as of Q3 2022.

Ergoteles reported no remaining MacroGenics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 75,200 MacroGenics shares in Q3 2022, an estimated $222K.
Ergoteles first reported a position in MacroGenics in Q4 2021 and held it in 2 quarters.
Ergoteles's MacroGenics position peaked at $515K in Q4 2021.
135 funds tracked by Wall St. Rank held MacroGenics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.